Background:
Avelumab is an immunotherapy that helps the immune system find and attack cancer cells.
Cabozantinib is a targeted therapy that blocks certain proteins cancer cells need to grow and spread.
Researchers think combining these two drugs may control the cancer better than immunotherapy alone.
The Trial:
The trial is testing whether adding cabozantinib to avelumab (an immunotherapy drug) can help patients live longer than taking avelumab alone after finishing initial chemotherapy.
Participants will be randomly assigned to one of the following treatment groups:
- Avelumab Alone
- Avelumab + Cabozantinib
The trial is not “blind”, so both you and your doctor will know which therapy you are receiving.
Basic Eligibility:
- Must have confirmed urothelial carcinoma of the renal pelvis
- Cancer must have spread and can’t be removed by surgery
- Must have already received one line of platinum-based chemotherapy
Additional eligibility criteria will apply. Please speak to your doctor.
| Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
|---|---|---|---|
| Hospital / Cancer CentreCross Cancer Institute | Principal InvestigatorNot Given | LocationEdmonton, AB | Trial StatusActive, not recruiting |
| Hospital / Cancer CentrePrincess Margaret Hospital | Principal InvestigatorNot Given | LocationToronto, ON | Trial StatusActive, not recruiting |
| Hospital / Cancer CentreAllan Blair Cancer Centre | Principal InvestigatorNot Given | LocationRegina, SK | Trial StatusActive, not recruiting |
| Hospital / Cancer CentreSaskatoon Cancer Centre | Principal InvestigatorNot Given | LocationSaskatoon, SK | Trial StatusActive, not recruiting |

























































